Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 458

1.

Nanopore metagenomics enables rapid clinical diagnosis of bacterial lower respiratory infection.

Charalampous T, Kay GL, Richardson H, Aydin A, Baldan R, Jeanes C, Rae D, Grundy S, Turner DJ, Wain J, Leggett RM, Livermore DM, O'Grady J.

Nat Biotechnol. 2019 Jul;37(7):783-792. doi: 10.1038/s41587-019-0156-5. Epub 2019 Jun 24.

PMID:
31235920
2.

Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infections.

Horner C, Mushtaq S, Livermore DM; BSAC Resistance Surveillance Standing Committee .

J Antimicrob Chemother. 2019 Jul 1;74(7):1940-1944. doi: 10.1093/jac/dkz133.

PMID:
31032858
3.

Doxycycline in UK guidelines for hospital-acquired pneumonia: where is the evidence base?-authors' response.

Russell AH, Horner C, Livermore DM, MacGowan AP.

J Antimicrob Chemother. 2019 Jun 1;74(6):1767. doi: 10.1093/jac/dkz105. No abstract available.

PMID:
30915460
4.

Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing Enterobacteriaceae.

Mushtaq S, Vickers A, Woodford N, Haldimann A, Livermore DM.

J Antimicrob Chemother. 2019 Apr 1;74(4):953-960. doi: 10.1093/jac/dky522.

PMID:
30590470
5.

Evaluation of multiplex tandem PCR (MT-PCR) assays for the detection of bacterial resistance genes among Enterobacteriaceae in clinical urines.

Schmidt K, Stanley KK, Hale R, Smith L, Wain J, O'Grady J, Livermore DM.

J Antimicrob Chemother. 2019 Feb 1;74(2):349-356. doi: 10.1093/jac/dky419.

PMID:
30476137
6.

Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa.

Edgeworth JD, Merante D, Patel S, Young C, Jones P, Vithlani S, Wyncoll D, Roberts P, Jones A, Den Nagata T, Ariyasu M, Livermore DM, Beale R.

Clin Infect Dis. 2019 May 17;68(11):1932-1934. doi: 10.1093/cid/ciy963.

7.

OXA-1 β-lactamase and non-susceptibility to penicillin/β-lactamase inhibitor combinations among ESBL-producing Escherichia coli.

Livermore DM, Day M, Cleary P, Hopkins KL, Toleman MA, Wareham DW, Wiuff C, Doumith M, Woodford N.

J Antimicrob Chemother. 2019 Feb 1;74(2):326-333. doi: 10.1093/jac/dky453.

PMID:
30388219
8.

The 2018 Garrod Lecture: Preparing for the Black Swans of resistance.

Livermore DM.

J Antimicrob Chemother. 2018 Nov 1;73(11):2907-2915. doi: 10.1093/jac/dky265.

PMID:
30351434
9.

Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae.

Livermore DM, Mushtaq S, Doumith M, Jamrozy D, Nichols WW, Woodford N.

J Antimicrob Chemother. 2018 Dec 1;73(12):3336-3345. doi: 10.1093/jac/dky363.

PMID:
30247546
10.

Doxycycline in UK guidelines for hospital-acquired pneumonia: where is the evidence base?

Russell AH, Horner C, Livermore DM, MacGowan AP.

J Antimicrob Chemother. 2018 Nov 1;73(11):3212-3215. doi: 10.1093/jac/dky306. No abstract available.

PMID:
30085229
11.

Activity of RX-04 Pyrrolocytosine Protein Synthesis Inhibitors against Multidrug-Resistant Gram-Negative Bacteria.

Vickers A, Mushtaq S, Woodford N, Doumith M, Livermore DM.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00689-18. doi: 10.1128/AAC.00689-18. Print 2018 Aug.

12.

Pseudomonas aeruginosa sequence type 357 with VEB extended-spectrum β-lactamases in the UK: relatedness and resistance.

Greenwood B, Meunier D, Hopkins KL, Pike R, Ivanov Z, Turton JF, Hill R, Woodford N, Livermore DM.

Int J Antimicrob Agents. 2018 Aug;52(2):301-302. doi: 10.1016/j.ijantimicag.2018.03.013. Epub 2018 Mar 23. No abstract available.

PMID:
29580931
13.

Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party.

Hawkey PM, Warren RE, Livermore DM, McNulty CAM, Enoch DA, Otter JA, Wilson APR.

J Antimicrob Chemother. 2018 Mar 1;73(suppl_3):iii2-iii78. doi: 10.1093/jac/dky027. Review.

PMID:
29514274
14.

Re: "Comparison of antipseudomonal betalactams for febrile neutropenia empiric therapy: systematic review and network metaanalysis" by Horita et al.

Averbuch D, Orasch C, Mikulska M, Livermore DM, Viscoli C, Gyssens IC, Kern WV, Klyasova G, Marchetti O, Engelhard D, Akova M, Calandra T, Cordonnier C; ECIL4 antibacterial group, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN.

Clin Microbiol Infect. 2018 Jun;24(6):662-663. doi: 10.1016/j.cmi.2018.01.012. Epub 2018 Feb 2. No abstract available.

15.

The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial.

Hammond M, Clark AB, Cahn AP, Chilvers ER, Fraser WD, Livermore DM, Maher TM, Parfrey H, Swart AM, Stirling S, Thickett D, Whyte M, Wilson A.

Trials. 2018 Feb 5;19(1):89. doi: 10.1186/s13063-018-2453-6.

16.

Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.

Livermore DM, Meunier D, Hopkins KL, Doumith M, Hill R, Pike R, Staves P, Woodford N.

J Antimicrob Chemother. 2018 Mar 1;73(3):648-657. doi: 10.1093/jac/dkx438.

PMID:
29228202
17.

Genomic sequences of Streptococcus agalactiae with high-level gentamicin resistance, collected in the BSAC bacteraemia surveillance.

Doumith M, Mushtaq S, Martin V, Chaudhry A, Adkin R, Coelho J, Chalker V, MacGowan A, Woodford N, Livermore DM; BSAC Resistance Surveillance Standing Committee.

J Antimicrob Chemother. 2017 Oct 1;72(10):2704-2707. doi: 10.1093/jac/dkx207.

PMID:
29091185
18.

Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens.

Livermore DM, Mushtaq S, Warner M, Turner SJ, Woodford N.

J Antimicrob Chemother. 2018 Jan 1;73(1):126-133. doi: 10.1093/jac/dkx360.

PMID:
29059308
19.

AmpC β-lactamase induction by avibactam and relebactam.

Livermore DM, Jamrozy D, Mushtaq S, Nichols WW, Young K, Woodford N.

J Antimicrob Chemother. 2017 Dec 1;72(12):3342-3348. doi: 10.1093/jac/dkx298.

PMID:
28962008
20.

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an In Vitro Infection Model.

VanScoy BD, Tenero D, Turner S, Livermore DM, McCauley J, Conde H, Bhavnani SM, Rubino CM, Ambrose PG.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01052-17. doi: 10.1128/AAC.01052-17. Print 2017 Dec.

21.

Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles.

Livermore DM, Mushtaq S, Meunier D, Hopkins KL, Hill R, Adkin R, Chaudhry A, Pike R, Staves P, Woodford N; BSAC Resistance Surveillance Standing Committee.

J Antimicrob Chemother. 2017 Aug 1;72(8):2278-2289. doi: 10.1093/jac/dkx136.

22.

Major role of pKpQIL-like plasmids in the early dissemination of KPC-type carbapenemases in the UK.

Doumith M, Findlay J, Hirani H, Hopkins KL, Livermore DM, Dodgson A, Woodford N.

J Antimicrob Chemother. 2017 Aug 1;72(8):2241-2248. doi: 10.1093/jac/dkx141.

PMID:
28498924
23.

WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.

Mushtaq S, Vickers A, Woodford N, Livermore DM.

J Antimicrob Chemother. 2017 Jun 1;72(6):1688-1695. doi: 10.1093/jac/dkx035.

PMID:
28333319
24.

A Risk Assessment of Antibiotic Pan-Drug-Resistance in the UK: Bayesian Analysis of an Expert Elicitation Study.

Carter D, Charlett A, Conti S, Robotham JV, Johnson AP, Livermore DM, Fowler T, Sharland M, Hopkins S, Woodford N, Burgess P, Dobra S.

Antibiotics (Basel). 2017 Mar 7;6(1). pii: E9. doi: 10.3390/antibiotics6010009.

25.

OXA-48-like carbapenemases in the UK: an analysis of isolates and cases from 2007 to 2014.

Findlay J, Hopkins KL, Loy R, Doumith M, Meunier D, Hill R, Pike R, Mustafa N, Livermore DM, Woodford N.

J Antimicrob Chemother. 2017 May 1;72(5):1340-1349. doi: 10.1093/jac/dkx012.

PMID:
28199647
26.

In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria.

Livermore DM, Mushtaq S, Warner M, Vickers A, Woodford N.

J Antimicrob Chemother. 2017 May 1;72(5):1373-1385. doi: 10.1093/jac/dkw593.

PMID:
28158732
27.

Rise of multidrug-resistant non-vaccine serotype 15A Streptococcus pneumoniae in the United Kingdom, 2001 to 2014.

Sheppard C, Fry NK, Mushtaq S, Woodford N, Reynolds R, Janes R, Pike R, Hill R, Kimuli M, Staves P, Doumith M, Harrison T, Livermore DM.

Euro Surveill. 2016 Dec 15;21(50). pii: 30423. doi: 10.2807/1560-7917.ES.2016.21.50.30423.

28.

Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study.

Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasević AT, Cantón R, Carmeli Y, Friedrich AW, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Nordmann P, Poirel L, Rossolini GM, Seifert H, Vatopoulos A, Walsh T, Woodford N, Monnet DL; European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group.

Lancet Infect Dis. 2017 Feb;17(2):153-163. doi: 10.1016/S1473-3099(16)30257-2. Epub 2016 Nov 18.

PMID:
27866944
29.

Etest® versus broth microdilution for ceftaroline MIC determination with Staphylococcus aureus: results from PREMIUM, a European multicentre study.

Cantón R, Livermore DM, Morosini MI, Díaz-Regañón J, Rossolini GM; PREMIUM Study Group.

J Antimicrob Chemother. 2017 Feb;72(2):431-436. doi: 10.1093/jac/dkw442. Epub 2016 Oct 20.

30.

Identification of bacterial pathogens and antimicrobial resistance directly from clinical urines by nanopore-based metagenomic sequencing.

Schmidt K, Mwaigwisya S, Crossman LC, Doumith M, Munroe D, Pires C, Khan AM, Woodford N, Saunders NJ, Wain J, O'Grady J, Livermore DM.

J Antimicrob Chemother. 2017 Jan;72(1):104-114. Epub 2016 Sep 25.

PMID:
27667325
31.

New insights into the regulatory pathways associated with the activation of the stringent response in bacterial resistance to the PBP2-targeted antibiotics, mecillinam and OP0595/RG6080.

Doumith M, Mushtaq S, Livermore DM, Woodford N.

J Antimicrob Chemother. 2016 Oct;71(10):2810-4. doi: 10.1093/jac/dkw230. Epub 2016 Jun 20.

PMID:
27330062
32.

Antimicrobial use and microbiological testing in district general hospital ICUs of the Veneto region of north-east Italy.

Benedetti P, Sefton AM, Menegozzo M, Guerriero C, Bordignon G, Da Rin G, Romualdi C, Pellizzer G, Livermore DM.

Eur J Clin Microbiol Infect Dis. 2016 Oct;35(10):1627-38. doi: 10.1007/s10096-016-2701-1. Epub 2016 Jun 15.

PMID:
27301585
33.

Multidrug-resistant (MDR) Gram-negative bacteria information leaflets.

Brown C, Livermore DM, Otter JA, Warren RE, Jenks P, Enoch DA, Newsholme W, Oppenheim B, Leanord A, McNulty C, Tanner G, Bennett S, Cann M, Bostock J, Collins E, Peckitt S, Ritchie L, Fry C, Hawkey P, Wilson AP.

J Hosp Infect. 2016 Jan;92(1):86-7. No abstract available.

PMID:
27158703
34.

Population structure of Escherichia coli causing bacteraemia in the UK and Ireland between 2001 and 2010.

Day MJ, Doumith M, Abernethy J, Hope R, Reynolds R, Wain J, Livermore DM, Woodford N.

J Antimicrob Chemother. 2016 Aug;71(8):2139-42. doi: 10.1093/jac/dkw145. Epub 2016 May 5.

35.

In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii.

Livermore DM, Mushtaq S, Warner M, Woodford N.

Antimicrob Agents Chemother. 2016 May 23;60(6):3840-4. doi: 10.1128/AAC.00436-16. Print 2016 Jun.

36.

KPC enzymes in the UK: an analysis of the first 160 cases outside the North-West region.

Findlay J, Hopkins KL, Doumith M, Meunier D, Wiuff C, Hill R, Pike R, Loy R, Mustafa N, Livermore DM, Woodford N.

J Antimicrob Chemother. 2016 May;71(5):1199-206. doi: 10.1093/jac/dkv476. Epub 2016 Feb 3.

37.

Prevention and control of multi-drug-resistant Gram-negative bacteria: recommendations from a Joint Working Party.

Wilson AP, Livermore DM, Otter JA, Warren RE, Jenks P, Enoch DA, Newsholme W, Oppenheim B, Leanord A, McNulty C, Tanner G, Bennett S, Cann M, Bostock J, Collins E, Peckitt S, Ritchie L, Fry C, Hawkey P.

J Hosp Infect. 2016 Jan;92 Suppl 1:S1-44. doi: 10.1016/j.jhin.2015.08.007. Epub 2015 Nov 16. No abstract available.

PMID:
26598314
38.

Interactions of OP0595, a Novel Triple-Action Diazabicyclooctane, with β-Lactams against OP0595-Resistant Enterobacteriaceae Mutants.

Livermore DM, Warner M, Mushtaq S, Woodford N.

Antimicrob Agents Chemother. 2015 Nov 9;60(1):554-60. doi: 10.1128/AAC.02184-15. Print 2016 Jan.

39.

Genetic environment of metallo-β-lactamase genes in Pseudomonas aeruginosa isolates from the UK.

Wright LL, Turton JF, Hopkins KL, Livermore DM, Woodford N.

J Antimicrob Chemother. 2015 Dec;70(12):3250-8. doi: 10.1093/jac/dkv263. Epub 2015 Aug 27.

PMID:
26318194
40.

Susceptibility testing challenges with ceftaroline, MRSA and a 1 mg/L breakpoint.

Livermore DM, Mushtaq S, Warner M, James D, Woodford N.

J Antimicrob Chemother. 2015 Dec;70(12):3259-66. doi: 10.1093/jac/dkv265. Epub 2015 Aug 27.

PMID:
26318188
41.

Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases.

Livermore DM, Mushtaq S, Warner M, Woodford N.

J Antimicrob Chemother. 2015 Nov;70(11):3032-41. doi: 10.1093/jac/dkv239. Epub 2015 Aug 25.

PMID:
26311835
42.

Pathogens of skin and skin-structure infections in the UK and their susceptibility to antibiotics, including ceftaroline.

Livermore DM, Mushtaq S, Warner M, James D, Kearns A, Woodford N.

J Antimicrob Chemother. 2015 Oct;70(10):2844-53. doi: 10.1093/jac/dkv179. Epub 2015 Jul 4.

PMID:
26142478
43.

In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase.

Livermore DM, Warner M, Jamrozy D, Mushtaq S, Nichols WW, Mustafa N, Woodford N.

Antimicrob Agents Chemother. 2015 Sep;59(9):5324-30. doi: 10.1128/AAC.00678-15. Epub 2015 Jun 22.

44.

OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'.

Morinaka A, Tsutsumi Y, Yamada M, Suzuki K, Watanabe T, Abe T, Furuuchi T, Inamura S, Sakamaki Y, Mitsuhashi N, Ida T, Livermore DM.

J Antimicrob Chemother. 2015 Oct;70(10):2779-86. doi: 10.1093/jac/dkv166. Epub 2015 Jun 18.

PMID:
26089439
45.

Narrative review of primary care point-of-care testing (POCT) and antibacterial use in respiratory tract infection (RTI).

Cooke J, Butler C, Hopstaken R, Dryden MS, McNulty C, Hurding S, Moore M, Livermore DM.

BMJ Open Respir Res. 2015 May 6;2(1):e000086. doi: 10.1136/bmjresp-2015-000086. eCollection 2015.

46.

Discontinuation of empirical antibiotic therapy in neutropenic leukaemia patients with fever of unknown origin is ethical.

Orasch C, Averbuch D, Mikulska M, Cordonnier C, Livermore DM, Gyssens IC, Klyasova G, Engelhard D, Kern W, Viscoli C, Akova M, Marchetti O; 4th European Conference on Infections in Leukemia (ECIL-4); joint venture of Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (IDWP-EBMT); Infectious Diseases Group of the European Organization for Research and Treatment of Cancer (IDG-EORTC); International Immunocompromised Host Society (ICHS); European Leukemia Net (ELN) and European Study Group on Infections in Immunocompromised Hosts of the European Society for Clinical Microbiology and Infectious Diseases (ESGICH-ESCMID).

Clin Microbiol Infect. 2015 Mar;21(3):e25-7. doi: 10.1016/j.cmi.2014.10.014. Epub 2014 Dec 18. No abstract available.

47.

Cephalosporinases associated with outer membrane vesicles released by Bacteroides spp. protect gut pathogens and commensals against β-lactam antibiotics.

Stentz R, Horn N, Cross K, Salt L, Brearley C, Livermore DM, Carding SR.

J Antimicrob Chemother. 2015 Mar;70(3):701-9. doi: 10.1093/jac/dku466. Epub 2014 Nov 27.

48.

Rapid identification of major Escherichia coli sequence types causing urinary tract and bloodstream infections.

Doumith M, Day M, Ciesielczuk H, Hope R, Underwood A, Reynolds R, Wain J, Livermore DM, Woodford N.

J Clin Microbiol. 2015 Jan;53(1):160-6. doi: 10.1128/JCM.02562-14. Epub 2014 Oct 29.

49.

Longitudinal trends and cross-sectional analysis of English national hospital antibacterial use over 5 years (2008-13): working towards hospital prescribing quality measures.

Cooke J, Stephens P, Ashiru-Oredope D, Charani E, Dryden M, Fry C, Hand K, Holmes A, Howard P, Johnson AP, Livermore DM, Mansell P, McNulty CA, Wellsteed S, Hopkins S, Sharland M.

J Antimicrob Chemother. 2015 Jan;70(1):279-85. doi: 10.1093/jac/dku328. Epub 2014 Oct 10.

PMID:
25304646
50.

Dominance of international 'high-risk clones' among metallo-β-lactamase-producing Pseudomonas aeruginosa in the UK.

Wright LL, Turton JF, Livermore DM, Hopkins KL, Woodford N.

J Antimicrob Chemother. 2015 Jan;70(1):103-10. doi: 10.1093/jac/dku339. Epub 2014 Sep 1.

PMID:
25182064

Supplemental Content

Loading ...
Support Center